Advanced search
1 file | 789.85 KB

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update

Author
Organization
Abstract
Background: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. Methods: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. Results: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. Conclusions: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.
Keywords
DOUBLE-BLIND, TO-SEVERE PSORIASIS, FACTOR-ALPHA BLOCKERS, SYSTEMATIC LITERATURE SEARCH, ANTI-INTERLEUKIN-17A MONOCLONAL-ANTIBODY, QUALITY-OF-LIFE, NECROSIS FACTOR THERAPY, PLACEBO-CONTROLLED TRIAL, RANDOMIZED CONTROLLED-TRIAL, MINIMAL DISEASE-ACTIVITY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 789.85 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Gossec, L, JS Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, et al. 2016. “European League Against Rheumatism (EULAR) Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies : 2015 Update.” Annals of the Rheumatic Diseases 75 (3): 499–510.
APA
Gossec, L., Smolen, J., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., et al. (2016). European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update. ANNALS OF THE RHEUMATIC DISEASES, 75(3), 499–510.
Vancouver
1.
Gossec L, Smolen J, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update. ANNALS OF THE RHEUMATIC DISEASES. 2016;75(3):499–510.
MLA
Gossec, L, JS Smolen, S Ramiro, et al. “European League Against Rheumatism (EULAR) Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies : 2015 Update.” ANNALS OF THE RHEUMATIC DISEASES 75.3 (2016): 499–510. Print.
@article{7221435,
  abstract     = {Background: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations. 
Methods: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. Levels of evidence and strengths of recommendations were allocated. 
Results: The updated recommendations comprise 5 overarching principles and 10 recommendations, covering pharmacological therapies for PsA from non-steroidal anti-inflammatory drugs (NSAIDs), to conventional synthetic (csDMARD) and biological (bDMARD) disease-modifying antirheumatic drugs, whatever their mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing on musculoskeletal involvement. The overarching principles address the need for shared decision-making and treatment objectives. The recommendations address csDMARDs as an initial therapy after failure of NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) inhibitor. bDMARDs targeting interleukin (IL) 12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate. If the first bDMARD strategy fails, any other bDMARD or tsDMARD may be used. 
Conclusions: These recommendations provide stakeholders with an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes in PsA, based on a combination of evidence and expert opinion.},
  author       = {Gossec, L and Smolen, JS and Ramiro, S and de Wit, M and Cutolo, M and Dougados, M and Emery, P and Landew{\'e}, R and Oliver, S and Aletaha, D and Betteridge, N and Braun, J and Burmester, G and Ca{\~n}ete, JD and Damjanov, N and FitzGerald, O and Haglund, E and Helliwell, P and Kvien, TK and Lories, R and Luger, T and Maccarone, M and Marzo-Ortega, H and McGonagle, D and McInnes, IB and Olivieri, I and Pavelka, K and Schett, G and Sieper, J and Van den Bosch, Filip and Veale, DJ and Wollenhaupt, J and Zink, A and van der Heijde, D},
  issn         = {0003-4967},
  journal      = {ANNALS OF THE RHEUMATIC DISEASES},
  language     = {eng},
  number       = {3},
  pages        = {499--510},
  title        = {European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies : 2015 update},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2015-208337},
  volume       = {75},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: